​

Day One Biopharmaceuticals (DAWN) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Day One Biopharmaceuticals Revenue Highlights

Latest Revenue (Y)

$131.16M

Latest Revenue (Q)

$39.80M

Main Segment (Y)

License

Day One Biopharmaceuticals Revenue by Period

Day One Biopharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$131.16M100.00%
2023-12-31-100.00%
2022-12-31-100.00%
2021-12-31-100.00%
2020-12-31-100.00%
2019-12-31--

Day One Biopharmaceuticals generated $131.16M in revenue during NA 2024, up 100.00% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Day One Biopharmaceuticals Revenue by Quarter

DateRevenueChange
2025-09-30$39.80M17.36%
2025-06-30$33.91M10.23%
2025-03-31$30.76M5.32%
2024-12-31$29.21M-68.85%
2024-09-30$93.76M1044.54%
2024-06-30$8.19M100.00%
2024-03-31--100.00%
2023-12-31$560.00K100.00%
2023-09-30-100.00%
2023-06-30-100.00%
2023-03-31-100.00%
2022-12-31-100.00%
2022-09-30-100.00%
2022-06-30-100.00%
2022-03-31-100.00%
2021-12-31-100.00%
2021-09-30-100.00%
2021-06-30-100.00%
2021-03-31-100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31--

Day One Biopharmaceuticals generated $39.80M in revenue during Q3 2025, up 17.36% compared to the previous quarter, and up 485.78% compared to the same period a year ago.

Day One Biopharmaceuticals Revenue Breakdown

Day One Biopharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
License$73.94M
Product$57.22M

Day One Biopharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (56.38%), and Product (43.62%).

Quarterly Revenue by Product

Product/ServiceSep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Product$38.52M$33.56M$30.50M$28.95M$20.07M$8.19M
License$1.27M$346.00K$258.00K$253.00K$73.69M-

Day One Biopharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 25: Product (96.80%), and License (3.20%).

Day One Biopharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ARVNArvinas$263.40M$41.90M
VALNValneva SE$153.70M$32.75M
DAWNDay One Biopharmaceuticals$131.16M$39.80M
GERNGeron$76.50M$47.23M
VIRVir Bio$74.20M$240.00K
RZLTRezolute--
REPLReplimune Group--
ATXSAstria Therapeutics-$706.00K
ERASErasca--
TYRATyra Biosciences--
AVBPArriVent BioPharma--

DAWN Revenue FAQ

What is Day One Biopharmaceuticals’s yearly revenue?

Day One Biopharmaceuticals's yearly revenue for 2024 was $131.16M, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. DAWN's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.

What is Day One Biopharmaceuticals’s quarterly revenue?

Day One Biopharmaceuticals's quarterly revenue for Q3 2025 was $39.8M, a 17.36% increase from the previous quarter (Q2 2025), and a -57.56% decrease year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $33.91M, a 10.23% increase from the previous quarter (Q1 2025), and a 313.92% increase year-over-year (Q2 2024). DAWN's quarterly revenue for Q1 2025 was $30.76M, a 5.32% increase from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024).

What is Day One Biopharmaceuticals’s revenue growth rate?

Day One Biopharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.

What are Day One Biopharmaceuticals’s revenue streams?

Day One Biopharmaceuticals's revenue streams in c 24 are License, and Product. License generated $73.94M in revenue, accounting 56.38% of the company's total revenue Product generated $57.22M in revenue, accounting 43.62% of the company's total revenue

What is Day One Biopharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Day One Biopharmaceuticals was License. This segment made a revenue of $73.94M, representing 56.38% of the company's total revenue.